Logo

BMS Presents Results of Deucravacitinib in P-II (PAISLEY) Study for the Treatment of Systemic Lupus Erythematosus at EULAR 2022

Share this
BMS Presents Results of Deucravacitinib in P-II (PAISLEY) Study for the Treatment of Systemic Lupus Erythematosus at EULAR 2022

BMS Presents Results of Deucravacitinib in P-II (PAISLEY) Study for the Treatment of Systemic Lupus Erythematosus at EULAR 2022

Shots:

  • The P-II (PAISLEY) study evaluating deucravacitinib (3/6mg, BID) vs PBO in 363 patients with mod. to sev. SLE
  • The study met its 1EPs of achieving SRI(4) @32wk., a greater proportion of patients at 3 & 6mg, BID dose achieved SRI(4) (58.2% & 49.5% vs 34.4%) while 12mg, qd had numerically higher SRI(4) responses & responses were sustained across all groups ~48wk.
  • The 2EPs showed clinical improvements @48wk, ≥50% reduction from baseline CLASI-50 & change in the active joint count, was well tolerated with the safety profile consistent with earlier trials with no evidence of laboratory abnormalities characteristic of JAK 1/2/3 inhibitorṣ. The company plans to advance the therapy in the P-III studies for SLE

Ref: BMS | Image: BMS

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions